PROutine: a feasibility study assessing surveillance of electronic patient reported outcomes and adherence via smartphone app in advanced cancer

Gesine Benze¹, Friedemann Nauck¹, Bernd Alt-Epping¹, Giuseppe Gianni², Thomas Bauknecht², Johannes Ettl¹, Anna Munte³, Luisa Kretzschmar⁴, Jan Gaertner⁵

¹Department of Palliative Medicine, University Medical Center Göttingen, Göttingen, Germany; ²AppPeople GmbH, Frankfurt am Main, Germany; ³Department of Gynecology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany; ⁴Department of Gynecology, Charité-University Medical Center Berlin CVK, Berlin, Germany; ⁵Center for Palliative Care Hildegard, Basel, Switzerland

Contributions: (I) Conception and design: J Gaertner, F Nauck, B Alt-Epping, G Gianni, T Bauknecht; (II) Administrative support: G Gianni, T Bauknecht; (III) Provision of study materials or patients: G Benze, J Ettl, A Munte, L Kretschmar; (IV) Collection and assembly of data: G Benze, J Ettl, A Munte, L Kretschmar, J Gaertner; (V) Data analysis and interpretation: J Gaertner; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: PD Dr. med. Jan Gaertner. Palliative Care Center Hildegard, Sankt Alban Ring 151, CH-4002 Basel, Switzerland. Email: Jan.gaertner@pzhi.ch.

Background: In advanced cancer, quality of life (QoL) is a major treatment goal. In order to achieve this, the identification of suffering by screening for patient-reported-outcomes (PROs, i.e., symptoms) is of utmost importance. The use of paper-pencil questionnaires is associated with significant shortcomings due to missing data, recall bias and transcription errors. Other than that, the electronic recording of PROs by mobile Health (mHealth) offers a number of advantages. The aim of this study was to test whether the routine assessment of PROs via a newly developed smartphone application (MeQoL®) is feasible.

Methods: A prospective, uncontrolled, multi-center, feasibility trial was performed in adult outpatients with advanced, solid cancer. Patients under anti-cancer therapy and with regular outpatient visits were eligible. Patients daily recorded the degree of perceived distress (NCCN Distress Thermometer®), pain intensity [average and worst [numerical rating scale (NRS), 0–10]], the number of breakthrough pain episodes (BPE) and ten questions from a modified version of the Edmonton Symptom Assessment Scale (ESAS). Weekly, five questions concerning different domains of QoL from the short-form 8 (SF-8) questionnaire were obtained. Also, patients recorded the intake of their opioid rescue medication. According to the main scope of the trial (feasibility), no primary endpoint was defined. Rather, the following main feasibility criteria were assessed: missing data, drop-out- and acceptance-rate, patient satisfaction, patients’ judgement of practicability, patients’ and physicians’ suggestions for improvement and basic clinical and demographic data of the participating patients. The study was registered in the German Clinical Trials Register (ID: DRKS00008761).

Results: In three German cancer centers, 40 patients [female: 28 (70%); average age, 57 years [range, 27–73 years; standard deviation (SD), 12]] were included. As three devices were lost on transport, 37 devices could be evaluated. The median investigation period per device was 99.5 days (SD, 31). Patient adherence in using the smartphone app to document their distress and symptoms was high and missing data were low: In median daily reviews were performed on 70 (SD, 29) of these days (70%) and median weekly recordings were 13 weeks (87%). Most often, patients recorded symptom intensity (89%, MIDOS) and distress (85%, NCCN thermometer). On feedback forms, patients reported a good to very good user friendliness of MeQoL® and a high motivation to use this tool again.

Conclusions: Even though participants were asked to record PROs rather frequently (daily), missing
Introduction

Quality of life (QoL): a major goal of care

Cancer is frequently associated with pain and other conditions that impair the patients’ QoL and result in significant suffering of the affected patients (1,2). This is relevant for patients in curative and palliative stages of the disease (1,2). QoL and the reduction or prevention of suffering is an important goal of care for all cancer patients in curative and palliative situations (2). It is known that already at diagnosis, many patients with incurable cancer suffer from burdensome symptoms (3). All too often, this suffering remains unidentified and thus untreated despite readily available therapeutic options (i.e., cancer pain management) (1,2).

Importance of patient-reported-outcomes (PROs)

A major reason for such unnecessary suffering is that burdening symptoms or other sources of distress can ideally be assessed via PROs, but despite their validated usefulness such PROs are not routinely documented in clinical routine (4). For example, te Boveldt et al. (5) found that pain in medical oncology outpatients is not systematically registered in their medical records. Basch et al. (6) reported findings from a recently performed randomized, controlled trial (RCT) that showed that if PROs were obtained and recorded routinely, QoL and other clinical outcomes of cancer patients improved substantially compared to those who received standard care. This could be due to both patient and clinician focusing more on actual symptoms, distress and in their development (worsening/improving). Clinicians react on basis of this information with adjusting symptom control management and as a result of that, QoL and other clinical outcomes improved. The same applies to research in the field of anti-cancer therapy (7). Here, too often clinical trials abstain from assessing, reporting and discussing PROs (7). This substantially impairs the appraisal of the study findings, because such information is essential to judge outcomes that are of utmost importance for the patients (8). Furthermore, PROs play a crucial role in the process of evaluating the benefit of new anti-cancer-therapies: the European Society for Medical Oncology (ESMO) as well as the American Society of Clinical Oncology (ASCO) have implemented PROs in their framework for evaluation of new therapies.

The potential role of mobile Health (mHealth)

Large studies show that paper- and web-based surveys provide data that are essentially equivalent (9). It is known that the documentation of PROs via conventional paper-pencil questionnaires is associated with significant shortcomings (10). For example, such paper-pencil solutions are prone to recall bias, and their use in clinical trials is associated with a large amount of missing data and transcription errors (10). In addition to that paper-pencil versions require printed questionnaires not being ecofriendly and being costly. The advantages of electronic PRO (ePRO) are that symptom data could automatically be scored and is available in easily interpretable reports to be viewed when the clinician meets the patient, data entry by staff is not required, data can be automatically transferred in real time to a computer server, which can lead to many different clinically relevant actions based on PRO scores, results can be added to the patient’s electronical medical record, score alerts can be generated to notify clinical staff of acute patient needs and patients can be immediately
provided electronically with educational material or advices (11). Furthermore, a clinician can easily review a patient's symptom data over time. Meanwhile, it is known that electronic versions of validated paper-pencil versions of simple narrative questionnaires that do not rely on the use of complex visual material (i.e., Rorschach test) do not need to be further tested for validity. In addition to overcoming the methodological problems mentioned above (recall bias etc.), mHealth solutions, supported by mobile devices facilitate the continuous surveillance of the patients' well-being in the home environment without relying on costly and difficult-to-schedule visits in the out-patient clinic (or study center) or follow-up phone calls. This, for example, has been reported for the use of e-mail- or browser-based solutions (11). Because of the potential correlation of PROs to the adherence to the medication plan [i.e., pain intensity/breakthrough pain episodes (BPE) correlated to the correct use of opioids on demand], the real-time recording and visualization of, for example, pain intensity, pain episodes and (under-) use of on-demand medication, a mobile version like a smartphone app to collect these data may improve adherence and facilitate patient guidance (12). The same applies to the aspects of pharmacovigilance (i.e., side effects, or incorrect use) (13). Comprehensive and role-specific training for using ePRO systems are necessary (14).

**Aim of the study**

The aim of this study was to test whether the routine assessment of PROs via a newly developed smartphone application (MeQoL®) is feasible for outpatients with advanced cancer.

**Methods**

After registration of the study [German Clinical Trials Register (DRKS), ID: DRKS00008761] and approval by the local ethic committees, an open label prospective multicenter study was performed. The ethics committees of University Medical Center Göttingen, Klinikum rechts der Isar of the Technical University Munich and of the University Medical Center Berlin gave positive statements (ID: Göttingen, 13/11/14; Munich, 190/50S; Berlin, agreement to statement of Göttingen). Adult (>18 years) outpatients with advanced, solid cancer were eligible if they were routinely scheduled to receive at least monthly appointments in the outpatient clinic of the three participating cancer centers. The ability to use a smartphone app or the self-confidence and ability to learn it were preconditions to take part. In each center ten patients ought to be included. The key exclusion criteria were diagnosis of severe psychiatric comorbidities, psychomotor impairments, or inability to speak and write German. Also, patients near the end of life were not approached because of their vulnerability, their focus on other existential things other than taking part in a study and because of assumed drop out before end of study. “End of life” was defined via the “surprise question” for three months (“Would you be surprised if your patient died within the next three months?”) (15). Sampling was performed on several randomly chosen days by asking the oncologist responsible for outpatient clinic which patients of the present day would meet inclusion criteria.

After providing informed consent, patients were instructed how to use the smartphone application. Instructions were given by a physician in a face to face conversation demonstrating the use and the content of the app going through the program in a live demonstration. There were no process level changes. Patients who agreed to take part in the study were familiar with computer literacy including smartphone use. The time needed for this instruction was recorded. Additionally, each patient received a handbook explaining the usage of the device and the app.

Daily, patients recorded the degree of perceived distress (measure: NCCN Distress Thermometer®) via the smartphone app MeQoL® (Figure 1). Additionally, pain intensity (average and worst), the number of BPE and ten questions from a shortened Minimal Documentation System (MIDOS) questionnaire, which is a simplified version of the Edmonton Symptom Assessment Scale (ESAS), were asked to be documented. Additionally, patients recorded five questions [from the Short-form 8 questionnaire (SF-8)] concerning different domains of QoL (reduction of activities, pain intensity, reduction of social contact, distress by emotional problems, restrictions in everyday life) weekly. For these recordings, the patients were reminded via push-up notifications. Patients were allowed to record PROs on more than these predefined occasions. Monitoring of symptoms was not followed by clinical actions because feasibility of using the app itself by the patient was in focus of this study. Analyzing doctor-patient interaction with the help of this app and effect on medication adjustment by the physician and symptom relief of the patient will be next steps in a new study. According to the main scope of the trial (feasibility), no clinical outcome was defined as a primary endpoint. Rather, the following
main outcome measures were assessed descriptively: missing data, drop-out- and acceptance-rate, patient satisfaction and patient judgement of practicability, patients' and physicians' suggestions for improvement, demographic and clinical data of the patients. Testing for statistical significance of association between different parameters was not attempted, in order to avoid multiple testing errors in the absence of an obvious a priori hypothesis. Rather, the results were evaluated descriptively.

**Results**

In the period from March 2015 to December 2015, 40 patients from three German cancer centers were included in the study. One institution had previously canceled participation in the study due to organizational reasons. Because of pragmatically considerations, no additional center was included in order to carry on in time. One center doubled therefore the number of patients included so the number of patients was 40. From 40 devices that were sent by mail, three devices were not delivered and thus could not be evaluated since the data was stored only in the device. The data from all received devices could be analyzed. Missing feedback sheets were observed and registered (Table 1).

Forty of the requested 56 patients (71%) participated in the study. Thirty-seven devices (92.5%) could be evaluated. Eighty-five percent (34/40) of the record sheets and 75% (30/40) of the feedback forms were available and could be evaluated (Table 1). The reported duration for the training of the patients in the handling of the device was 20 to 30 minutes. The reasons for refusing participation in the study were mostly personal in nature or justified with an uncertainty regarding the device and the technology. Reasons for refusal of participation were not correlated with age or sex of the patient. The majority of patients...
was between 50 and 70 years old [average, 57 years (range, 27–73 years; SD, 12)] and was female (28/40), four patients were older than 70 years (Figure 2).

The median overall investigation period per device was 99.5 days [defined as days between the first and last active recording in the MeQoL® (SD, 31; range, 16–175 days)]. In the median daily reviews (defined as a day on which an active use of a MeQoL® component was recorded) were performed on 70 days (70%) (range, 9–119 days; SD, 29). On 4% of the days the app was used more than once (Table 2). Median weekly recordings were performed on 13 weeks (87%) (Table 3). Also, the patients frequently used the possibility of weekly recordings (Table 3). Both daily and weekly recordings seem to be appropriate. Daily recording makes sense to be performed in the evening.

**Evaluation and feedback**

Feedback was given by 30 patients but not everybody answered every question. The majority of patients, 26 of 29 (86%), rated the usability as good to very good, and 27 of 30 patients (90%) would use the mobile device based app again. The personal benefit from monitoring was rated good and very good by 16 (53%) patients (Table 4).

Five physicians gave feedback. They rated usability as good to very good, all would want to use the mobile device based app again, and everybody saw a personal benefit by using it. They appreciated the most the fact that such an app is available and graphic data analysis.

To improve the app, it was suggested to enlarge writing, a possibility of type in text, to add questions concerning weight, health/feeling good, sexuality and collateral symptoms as mucositis. Patients recommended adding an acoustic signal to be reminded to use the app.

**Exemplary extract of the data evaluation of a device**

The recorded values (QoL, pain episodes, pain rescue medication, MIDOS questions, SF-8) can be reproduced and displayed in any combination. This allowed a direct comparison of individual values (two or more). QoL, pain intensity and pain episodes as well as taking rescue medication for pain were recorded and were visualized in graphs (Figure 3). It shows that rescue medication for pain was taken when pain intensity and pain events increased and QoL had declined. With the use of the rescue medication for pain QoL improved, and pain intensity decreased. (Figure 3).

**Discussion**

**Summary and interpretation of findings**

Increasing use of smartphones and apps in the general population suggests the collection of individual health data, in order to optimize treatment in pain patients, for example. In this feasibility trial, adherence for the smartphone application was high, while missing data and dropout rate were low, even though a quite frequent (daily) recording was demanded (Tables 2, 3). These findings met our a priori definition (less than 30% refusal) of feasibility. Comparison of the rates of missing data and drop out using conventional paper-pencil versions of PRO questionnaires (10) with the

![Figure 2](image_url) Age of the participating patients (n=40). Ø, mean (age).

<table>
<thead>
<tr>
<th>Usage</th>
<th>Median in total</th>
<th>Center</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Göttingen</td>
</tr>
<tr>
<td>Days of usage</td>
<td>99.5</td>
<td>93.0</td>
</tr>
<tr>
<td>Days app was used</td>
<td>70.0 (70%)</td>
<td>68.5 (74%)</td>
</tr>
<tr>
<td>Several times used/day</td>
<td>4.0 (4%)</td>
<td>7.0 (8%)</td>
</tr>
</tbody>
</table>
results of this study shows that the smartphone version is at least comparable or even superior to conventional PRO assessment. In addition, it has already been demonstrated that in contrast to electronic recording, paper-pencil questionnaires are prone to recall bias for example because of lost questionnaire papers and illegible writing (10). Furthermore, recall bias could be due to patients who did not remember their symptoms well enough in the time of recording them. In their feedback, patients mentioned that it would be helpful to have f.e. acoustic reminders to fill out the questionnaire. Patients’ satisfaction with MeQoL® was high and many participants recorded symptoms and distress more often than in the predefined intervals (Tables 2, 3). Also, individual assessment of visualized correlation of pain intensity, pain episodes and intake of on-demand medication (Figure 3) can be used to identify shortcomings in the patients’ adherence to treatment and to facilitate communication about these issues.

A simple and inexpensive iPod based mHealth solution (MeQoL®) enables the patient to routinely document the current QoL corresponding to intensity of symptoms and intake of rescue medication.

Cloud-based solutions could have reduced the number of missing data related to lost devices and data which is accessible from everywhere any time by authorized persons. Furthermore, it would have offered a brought range of possibilities for evaluation and interaction.

### Improvement of MeQoL®-app and implications for further research

In order to improve user friendliness for patients, reminding functions for data input could be adjusted. For doctors, “red flags”, e.g., for high symptom scores and frequently used rescue medication, might be helpful to react quickly to adjust medication or to arrange diagnostic procedures. A future goal is to further individualize apps adapted to the needs of patients and care givers. Accessibility of data for physicians independent of interface meetings with patients could be simplified by clouds.

Further research could be performed concerning how patients and physicians or other care givers could ideally be motivated and trained in using such apps for collecting health information and how to interpret the data.

### Limitations of the study

Limitations of this study were especially the open label design and low number of patients. Furthermore, only German speaking people could take part because no other

---

**Table 3** Evaluation of the average app usage for the weekly recording, compared to the total investigation period (weeks, treatment centers as mean value)

<table>
<thead>
<tr>
<th>Usage</th>
<th>Median in total</th>
<th>Göttingen</th>
<th>Munich</th>
<th>Berlin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weeks app could be used by the patient</td>
<td>15.0</td>
<td>13.0</td>
<td>14.5</td>
<td>16.0</td>
</tr>
<tr>
<td>Weeks app was actively used by the patient</td>
<td>13.0 (87%)</td>
<td>13.0 (100%)</td>
<td>12.5 (86%)</td>
<td>13.0 (81%)</td>
</tr>
<tr>
<td>Several times used/week</td>
<td>1 (7%)</td>
<td>1.5 (12%)</td>
<td>0</td>
<td>1 (6%)</td>
</tr>
</tbody>
</table>

**Table 4** Feedback of patients

<table>
<thead>
<tr>
<th>Ranking</th>
<th>User friendliness</th>
<th>Would use app again</th>
<th>Perceived personal benefit</th>
<th>Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very bad (2−)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Poor (1−)</td>
<td>0</td>
<td>0</td>
<td>4 (13%)</td>
<td>1 (3%)</td>
</tr>
<tr>
<td>Medium (0)</td>
<td>3 (10%)</td>
<td>3 (10%)</td>
<td>9 (30%)</td>
<td>5 (16%)</td>
</tr>
<tr>
<td>Good (1+)</td>
<td>13 (43%)</td>
<td>16 (53%)</td>
<td>10 (33%)</td>
<td>13 (43%)</td>
</tr>
<tr>
<td>Very good (2+)</td>
<td>13 (43%)</td>
<td>11 (37%)</td>
<td>6 (20%)</td>
<td>10 (33%)</td>
</tr>
</tbody>
</table>
language options for the app were provided. The individual benefit of data documentation could not be evaluated because data was not routinely discussed with the doctor and therefore had no impact on therapeutically decisions.

Conclusions

Using digital documentation of PROs via smartphone app is characterized by a high patient satisfaction and judgment of practicability. Routine screening for symptom burden and QoL issues demonstrates significantly improved clinical outcomes, and the insufficient assessment of PROs in cancer research massively impairs the interpretability of study results. For the individual patient, MeQoL® may also allow for monitoring adherence to pharmacotherapy and can facilitate patient guidance.

Acknowledgements

We thank every team member in Berlin, Göttingen and Munich who has made it possible that this study could be performed, either by active contribution to the study itself or by allowing investigators to have time resources for working on the study. We thank Gerhild Becker for proofreading the final manuscript.

Funding: The conduction of this study was promoted by a research grant from TEVA Specialties.

Footnote

Conflicts of Interest: B Alt-Epping received honoraria from TEVA, Kyowa Kirin, Roche, BMS, Amgen, and Novartis; T Bauknecht was employed as senior medical scientific liaison by Teva Germany; G Benze declares no conflicts of interest; J Ettl received honoraria from TEVA, Pfizer, and Roche Pharma; J Gaertner received research grants and honoraria from TEVA, Kyowa Kirin, Mundipharma, Pfizer, Sanofi-Aventis; G Gianni is employee of AppPeople; L Kretzschmar declares no conflicts of interest; A Munte declares no conflicts of interest; F Nauck received honoraria from Roche Pharma, Mundipharma, Archimedes and TEVA.

Ethical Statement: The ethics committees of University Medical Center Göttingen, Klinikum rechts der Isar of the Technical University Munich and of the University Medical Center Berlin gave positive statements (ID: Göttingen, 13/11/14; Munich, 190/50S; Berlin, agreement to statement of Göttingen). All patients have provided written informed content.

References


